Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
HOME > BUSINESS
BUSINESS
- Poxel Eyeing Japan as 1st Market for Its Lead Diabetes Candidate: CEO
February 6, 2018
- PorMedTec to Support Development Using Disease Model Pigs, Clients Already Include One Major Drug Maker
February 6, 2018
- Asahi Kasei Rolls Out Sanofi’s RA Med Kevzara
February 6, 2018
- Tagrisso Put on Priority Path in Japan for 1st-Line EGFR-Mutated NSCLC
February 6, 2018
- Japan Ethical Drug Market Projected at 9.6 Trillion Yen in 2024: Fuji Keizai
February 5, 2018
- Keiko Oishi to Head CMIC Holdings from April 1, with Pres. Nakamura Continuing as Chairman and CEO
February 5, 2018
- Drug Pricing Reform Could Cause “Crustal Change” in Industry Structure: Chugai President
February 2, 2018
- Chugai Notches Up Record Earnings in 2017 on Bullish Exports, Milestones
February 2, 2018
- Roche Diagnostics’ ALK CDx Ventana Filed for Add’l Use for Alecensa
February 2, 2018
- Meiji’s Parkinson’s Candidate Hits Goal in Japan PII/III, Filing Planned for 2018
February 2, 2018
- IMS Japan, Quintiles Japan to Change Names in April
February 1, 2018
- Astellas Taps EVP Yasukawa as Next CEO
February 1, 2018
- Hisamitsu’s Transdermal Schizophrenia Med Hits Primary Endpoint: US PIII
February 1, 2018
- Ferring Beefing Up Reproductive Health Biz in Japan, Sets Up Specialized Sales Team
January 31, 2018
- Sunovion’s Parkinson’s Candidate Hits PIII Primary Endpoint, US Filing Set for Spring
January 31, 2018
- Pfizer Files Japan NDA for Next-Gen ALK Inhibitor Lorlatinib
January 31, 2018
- US FDA Fast-Tracks Takeda’s Zika Vaccine Candidate
January 31, 2018
- Otsuka Bags US$10 Million Grant from Gates Foundation for Development of Anti-TB Drug
January 31, 2018
- Hiroshima Couple Served with Arrest Warrant over Counterfeit Harvoni
January 30, 2018
- Novartis Seeks Ankylosing Spondylitis Nod for Cosentyx in Japan
January 30, 2018
ページ
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…